Galmed Pharma (GLMD) Reports In-Line Q1 EPS

Galmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Cloudastructure restructures preferred stock, issues $1.3M promissory note